NEK6 and breast carcinoma: In all three cell lines tested, HEK293, the breast cancer cell line model MCF‐7, and U2‐OS cells, overexpression of the active NEK6 kinase reduced transcriptional activity in a dose‐dependent manner, an effect not observed with the kinase‐inactive NEK6 variant.